Disease: Myelofibrosis
- 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management
- A Case Report of Fedratinib-Associated Uveitis
- A lasso and random forest model using flow cytometry data identifies primary myelofibrosis
- A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
- A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis
- A rare case of primary myelofibrosis with novel cytogenetic abnormality - deletion 4q25
- A Rare MPIG6B Gene Mutation in a Saudi Adolescent Male With Thrombocytopenia, Anemia, and Myelofibrosis: A Case Report
- A Rare Presentation of Extramedullary Hematopoiesis as an Adrenal Mass: A Case Report
- A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery
- A Unique Presentation of Peripheral T Cell Lymphoma: Diagnosis Behind the Deceiving Dry Tap
- Acute invasive fungal sinusitis with orbital tip syndrome in patients on long-term use of ruxolitinib: a case report
- Acute panmylelosis with myelofibrosis - A rare case report with review of literature
- ADAMTS13, von Willebrand Factor, Platelet Microparticles, Factor VIII, and Impact of Somatic Mutations in the Pathogenesis of Splanchnic Vein Thrombosis Associated with BCR-ABL-Negative Myeloproliferative Neoplasms
- Adult-onset multifocal kaposiform hemangioendothelioma in the bone marrow, lung, liver, and brain: a case report
- Analysis of the factors influencing the severity of coronavirus disease 2019 in patients with myeloproliferative neoplasms based on an online questionnaire
- Application Value of 68 Ga-FAPI PET/CT in the Evaluation of Myelofibrotic Diseases
- Application Value of 68Ga-FAPI PET/CT in the Evaluation of Myelofibrotic Diseases
- Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis
- Bone marrow findings post allogeneic transplant for myeloproliferative neoplasms and chronic myelomonocytic leukemia with increased fibrosis
- Broad next generation integrated sequencing of myelofibrosis identifies disease-specific and age-related genomic alterations
- Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations
- Cabot rings in a cat with myeloproliferative disease
- Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
- CCN2/CTGF expression does not correlate with fibrosis in myeloproliferative neoplasms, consistent with noncanonical TGF-beta signaling driving myelofibrosis
- Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies
- Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
- Chronic myeloproliferative neoplasms with concomitant <em>CALR</em> mutation and <em>BCR::ABL1</em> translocation: diagnostic and therapeutic implications of a rare hybrid disease
- Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters
- Comparison of haploidentical transplantation and single cord blood transplantation for myelofibrosis
- Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression
- CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis
- Deregulation of the p19/CDK4/CDK6 axis in Jak2(V617F) megakaryocytes accelerates the development of myelofibrosis
- Direct and indirect costs for patients with myeloproliferative neoplasms
- Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections
- Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis
- Electrochemical Behavior of Janus Kinase Inhibitor Ruxolitinib at a Taurine-Electropolymerized Carbon Paste Electrode: Insights into Sensing Mechanisms
- Epstein-Barr-Virus-Related Lymphoproliferative Disorder in a Patient With Primary Myelofibrosis: A Case Report and Literature Review
- Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
- Essential thrombocythaemia: A contemporary approach with new drugs on the horizon
- Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis
- Evaluation of Janus Kinase 2 Exon 12 Mutations in Patients With JAK2V617F-negative Polycythemia Vera
- Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B-cell malignancies: Results from the CITADEL-101 study
- Exploring the molecular mechanisms between lymphoma and myelofibrosis
- Extensive Hepatic Infarction due to Polycythemia Vera
- Extramedullary haematopoiesis in a patient with myelofibrosis
- Focal Crescentic Glomerulonephritis Superimposed on Myeloproliferative Disease-Related Glomerulopathy in a Case of Myelofibrosis
- From primary myelofibrosis to chronic myeloid leukemia, BCR::ABL1+ B-Lymphoblastic leukemia, and back to primary myelofibrosis: An illustration of dynamic clonal evolution
- Gaucher Disease: A First Reported Adult Case in Indonesia
- Glucose-6-phosphate dehydrogenase deficiency with coinherited Gaucher disease: A rare association
- How I manage polycythemia
- Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus-based position paper from an ad hoc expert panel
- Impact of <em>CALR</em> and <em>JAK2</em>V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients
- Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT
- Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation
- In vivo ablation of NFκB cascade effectors alleviates disease burden in myeloproliferative neoplasms
- Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm
- Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
- Interferons in the treatment of myeloproliferative neoplasms
- Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib
- JAK inhibitor treatment-resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy?
- Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies
- Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post-essential thrombocythemia myelofibrosis: A case report
- Management of Patients with Early Myelofibrosis: A Discussion of Best Practices
- Methodological challenges in the development of endpoints for myelofibrosis clinical trials
- miR-146a(-/-) mice model reveals that NF-kappaB inhibition reverts inflammation-driven myelofibrosis-like phenotype
- Momelotinib bei Myelofibrose und Anämie
- Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
- Momelotinib in myelofibrosis
- Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial
- Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives
- Outcomes of allogeneic haematopoietic cell transplantation for myelofibrosis in children and adolescents: the retrospective study of the EBMT Paediatric Diseases WP
- Pathogenesis and Targeted Treatment Progress of Splenomegaly in Primary Myelofibrosis--Review
- Post polycythemia vera myelofibrosis with myelodysplastic-like progression in a patient with chronic lymphocytic leukemia
- Prognostic significance of bone marrow fibrosis in diffuse large B-cell lymphoma
- Real-World Electronic Medical Records Data Identify Risk Factors for Myelofibrosis and Can Be Used to Validate Established Prognostic Scores
- Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
- Renal extramedullary hematopoiesis as an epiphenomenon of bone marrow dysfunction in a patient with primary myelofibrosis: A rare case report
- Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
- Risk models in myelofibrosis-the past, present, and future
- Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study
- Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study
- Ruxolitinib associated psoas muscle tuberculosis abscess in a primary myelofibrosis woman: A case report and literature review
- SETBP1 sets the stage
- SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms
- Simultaneous blastic plasmacytoid dendritic cell neoplasm and myelofibrosis: A case report
- SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?
- Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study
- Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis
- Study of significance of bone marrow microvessel density in myeloproliferative neoplasms in correlation with CD34 blasts, mast cell count and fibrosis
- Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients
- Targeting bone marrow mechanosensation in myelofibrosis
- The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis
- The personal impact of living with a myeloproliferative neoplasm
- The Role of DNA Repair (<em>XPC</em>, <em>XPD</em>, <em>XPF</em>, and <em>XPG)</em> Gene Polymorphisms in the Development of Myeloproliferative Neoplasms
- TNF-α is a predictive marker in distinguishing myeloproliferative neoplasm and idiopathic erythrocytosis/thrombocytosis: development and validation of a non-invasive diagnostic model
- Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire
- Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT
- Triple a score (AAA: age, absolute neutrophil count and absolute lymphocyte count) and its prognostic utility in patients with overt fibrotic and prefibrotic myelofibrosis
- Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes
- Unraveling the crystal structure, stability and drug likeness of 1,3,4-oxadiazole derivatives against Myelofibrosis: a combined experimental and computational investigation